Rakovina Therapeutics Inc.
RKV.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 2.59M | 2.39M | 2.39M | 1.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 5.70M | 5.20M | 5.20M | 3.71M |
| Operating Income | -- | -5.70M | -5.20M | -5.20M | -3.71M |
| Income Before Tax | -- | -5.98M | -5.43M | -5.43M | -3.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -5.98 | -5.43 | -5.43 | -3.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -5.98M | -5.43M | -5.43M | -3.92M |
| EBIT | -- | -5.70M | -5.20M | -5.20M | -3.71M |
| EBITDA | -- | -5.32M | -4.82M | -4.82M | -3.33M |
| EPS Basic | -- | -0.41 | -0.43 | -0.43 | -0.38 |
| Normalized Basic EPS | -- | -0.19 | -0.27 | -0.20 | -0.17 |
| EPS Diluted | -- | -0.41 | -0.48 | -0.43 | -0.38 |
| Normalized Diluted EPS | -- | -0.19 | -0.27 | -0.20 | -0.17 |
| Average Basic Shares Outstanding | -- | 61.16M | 48.98M | 48.98M | 40.14M |
| Average Diluted Shares Outstanding | -- | 61.16M | 48.98M | 48.98M | 40.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |